Horizons in Cancer Research. Volume 65

Hiroto S. Watanabe (Editor)

Series: Horizons in Cancer Research
BISAC: MED062000

Clear

$250.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

This book presents original results on the leading edge of cancer research. Chapter One provides a comprehensive discussion to address the potential benefits of myricetin on cancer, diabetes, and neurodegenerative disease. It also discusses the underlined mechanism involved in the biological action of myricetin. Chapter Two discusses the clinical significance of vasculogenic mimicry. Chapter Three studies bacterial toxins as a direct cause of cancer. Chapter Four examines the immunological aspect of stroma in ovarian cancer. Chapter Five focuses on immune checkpoint inhibitors in the treatment of solid tumors. Chapter Six provides a review of targeting non-coding mitochondrial RNAs in gynecological and urinary malignancies. Chapter Seven explores the NF-κB signaling pathway, and its targeting in human cancer treatment. Chapter Eight analyzes the circadian rhythm and skin cancer prevention. The final section of this book is a short commentary on melanoma. (Imprint: Nova Biomedical)

Preface

Chapter 1. Health Promoting Activity of Myricetin: A Natural Flavonoid
Pushpendra Singh, Felix Bast, Shashank Kumar, and Pushpendu Kundu (Centre for Biosciences, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, Punjab, India, and others)

Chapter 2. Is Vasculogenic Mimicry a Hallmark of an Aggressive Tumor?
A. Vartanian, I. Golubewa and Z. Shprakh (Department of Experimental Diagnosis and Therapy of Tumors, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia)

Chapter 3. Educated Opinion: Bacterial Toxins as a Direct Cause of Cancer
G.K. Gogichadze and T.G.Gogichadze (Petre Shotadze Medical Academy, Tbilisi, Georgia)

Chapter 4. Immunological Aspects of Stroma in Ovarian Cancer
Rosekeila Simões Nomelini, Ana Carolinne da Silva, Millena Prata Jammal, and Eddie Fernando Candido Murta (Research Institute of Oncology (IPON); Discipline of Gynecology and Obstetrics, Federal University of Triângulo Mineiro (UFTM); Uberaba, Minas Gerais, Brazil)

Chapter 5. Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists
Ana Cvetanovic, Lazar Popovic, Nikola Zivkovic, Gorana Matovina-Brko, Sladjana Filipovic, Kostic Milos, Svetislav Vrbic, Ivica Pejcic (Department of Oncology, University Clinic of Nis, Serbia, and others)

Chapter 6. Targeting Non-Coding Mitochondrial RNAs (ncmtRNAs) in Gynecological and Urinary Malignancies: Universal Targets for the Development of an Efficient Therapy?
Vincenzo, Borgna, Lorena Lobos-González, Rodolfo Ávila, Mariela Araya, Verónica Burzio, Emmanuel Jeldes, Verónica Silva, Francisca Guevara, Constanza López, Claudio Villota, Eva Bustamante, Max Bendex, Cristopher Fitzpatrick, Luis Burzio, L.O. and Jaime Villegas (Servicio de Urología, Hospital Barros-Luco-Trudeau, Santiago, Chile, and others)

Chapter 7. The NF-κB Signaling Pathway and Its Targeting in Human Cancer Treatment
Ota Fuchs (Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 8. Nicotinamide Adenine Dinucleotide: The Circadian Rhythm and Skin Cancer Prevention
Jure Polak, Borut Poljšak, Raja Dahmane, and Andrej Starc (University of Ljubljana, Faculty of Medicine, Faculty of Health Sciences, Ljubljana, Slovenia

Short Communication: Melanoma

Index

You have not viewed any product yet.